丹蛭降糖胶囊联合达格列净治疗糖尿病肾病的临床疗效

Clinical Efficacy of Danzhi Jiangtang Capsules Combined with Dap agliflozin in the Treatment of Diabetic Nephropathy

目的:观察丹蛭降糖胶囊联合达格列净治疗30例糖尿病肾病的临床疗效。方法:选取了2020年9月—2021年9月期间在安徽中医药大学第一附属医院住院的确诊的糖尿病肾脏病患者,将所有患者按照随机数字法分为治疗组30例,对照组30例。对照组采用单一的达格列净(10 mg/d)治疗,观察组则采用丹蛭降糖胶囊(5.25g/d)和达格列净联合治疗,治疗周期为12周。检测并分析2组患者治疗前后的血糖相关指标:血清空腹血糖(FPG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1c)以及肾功能的相关指标:血肌酐(sCr)、尿素氮(BUN)、尿白蛋白排泄率(UAER)、尿微量白蛋白(mALB)。结果:2组治疗FPG、餐后2h血糖、HbA1c、BUN、Scr、UAER、mALB均有显著改善(P<0.05)。结论:丹蛭降糖胶囊联合达格列净可以明显改善2型糖尿病肾病患者血糖指标,并且降低尿蛋白,对糖尿病肾病具有良好的临床疗效,值得临床广泛应用。

Objective:To observe the clinical efficacy of Danzhi Jiangtang Capsules combined with Dapagliflozin in the treatment of 30 cases of diabetic nephropathy.Methods:Patients with diagnosed diabetic nephropathy who were hospitalized in the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine between September 2020 and September 2021 were selected,and all patients were randomly divided into a treatment group of 30 cases and a control group of 30 cases..The control group was treated with single dapagliflozin(10 mg/d),and the observation group was treated with Danzhi Jiangtang Capsules(5.25 g/d)and dapagliflozin combined treatment,and the treatment cycle was 12 weeks.Detect and analyze blood glucose-related indicators before and after treatment in the two groups:serum fasting blood glucose(FPG),postprandial 2h blood glucose(2hPG),glycosylated hemoglobin(HbA1c)and related indicators of renal function:serum creatinine(sCr),blood urea nitrogen(BUN),urinary albumin excretion rate(UAER),and urinary microalbumin(mALB).Results:FPG,postprandial 2h blood glucose,HbA1c,BUN,Scr,UAER,mALB were significantly improved in both groups(P<0.05).Conclusion:Danzhi Jiangtang Capsules combined with Dapagliflozin can significantly improve the blood sugar index in patients with type 2 diabetic nephropathy,and reduce urine protein.It has a good clinical effect on diabetic nephropathy and is worthy of extensive clinical application.